drugset
drugset / Trial / NCT04811404

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid

NCT04811404 ↗

Phase 4 Withdrawn New York State Psychiatric Institute
NaSingle-groupOpen-labelBasic science

Summary

This pilot study will ask whether omega three fatty acids have an antidepressant effect in bipolar depression by decreasing brain inflammation.

Timeline

Start
2021-03-19
Primary completion
2022-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ethyl Eicosapentaenoic Acid Unknown 1 g Oral

Indications

bipolar disorder